Archives of Neuroscience

Published by: Kowsar

Efficacy and Toxicity of Rituximab in Multiple Sclerosis

Zahra Tolou-Ghamari 1 , *
Author Information
1 Isfahan Deputy of Research, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Archives of Neuroscience: January 01, 2016, 3 (1); e30107
  • Published Online: January 9, 2016
  • Article Type: Review Article
  • Received: May 24, 2015
  • Revised: June 14, 2015
  • Accepted: June 22, 2015
  • DOI: 10.5812/archneurosci.30107

To Cite: Tolou-Ghamari Z. Efficacy and Toxicity of Rituximab in Multiple Sclerosis, Arch Neurosci. 2016 ; 3(1):e30107. doi: 10.5812/archneurosci.30107.

Copyright © 2016, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Mao CP, Brovarney MR, Dabbagh K, Birnbock HF, Richter WF, Del Nagro CJ. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS One. 2013; 8(11)[DOI][PubMed]
  • 2. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358(7): 676-88[DOI][PubMed]
  • 3. Tolou-Ghamari Z. Monitoring Tacrolimus (FK506) in Liver Transplant Recipients: A Consideration of Alternative Techniques and the Influence of Clinical Status. 1999; : 670
  • 4. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011; 378(9805): 1779-87[DOI][PubMed]
  • 5. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006; 180(1-2): 63-70[DOI][PubMed]
  • 6. Bar-Or A, Oliveira EM, Anderson DE, Krieger JI, Duddy M, O'Connor KC, et al. Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J Immunol. 2001; 167(10): 5669-77[PubMed]
  • 7. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. 2012; 209(5): 1001-10[DOI][PubMed]
  • 8. Akaishi T, Nakashima I. [Rituximab (anti-CD20) in neurological disorders]. Brain Nerve. 2014; 66(10): 1167-78[DOI][PubMed]
  • 9. Solal-Celigny P. Rituximab by subcutaneous route. Expert Rev Hematol. 2015; 8(2): 147-53[DOI][PubMed]
  • 10. Tolou-Ghamari Z. A Review of Geoepidemiological Differences of Multiple Sclerosis in Iran and Other Middle East Countries. Arch Neurosci. 2014; 2(3)[DOI]
  • 11. Tolou-Ghamari Z, Shaygannejad V, Ashtari F. Preliminary study related the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the isfahan kashani hospital. Int J Prev Med. 2013; 4-8[PubMed]
  • 12. Tolou-Ghamari Z. Antiepileptic drugs (AEDs) polypharmacy could lead to buried pharmacokinetic interactions due to CYP450. Drug Metab Lett. 2012; 6(3): 207-12[PubMed]
  • 13. Pierson ER, Stromnes IM, Goverman JM. B cells promote induction of experimental autoimmune encephalomyelitis by facilitating reactivation of T cells in the central nervous system. J Immunol. 2014; 192(3): 929-39[DOI][PubMed]
  • 14. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet. 2008; 9(7): 516-26[DOI][PubMed]
  • 15. Weber MS, Menge T, Lehmann-Horn K, Kronsbein HC, Zettl U, Sellner J, et al. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. Curr Pharm Des. 2012; 18(2): 209-19[PubMed]
  • 16. Feugier P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. Future Oncol. 2015; 11(9): 1327-42[DOI][PubMed]
  • 17. Kim SM, Park J, Kim SH, Park SY, Kim JY, Sung JJ, et al. Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects. PLoS One. 2013; 8(12)[DOI][PubMed]
  • 18. Schmalzing M, Tony HP. [B cell therapy of rheumatoid arthritis with rituximab. Practice-relevant aspects for the routine]. Z Rheumatol. 2015; 74(3): 250-7[DOI][PubMed]
  • 19. Zhang X, Guo X, Pan J. Increased levels of tumor necrosis factor-alpha involved in rituximab-related acute pulmonary fibrosis in diffuse large B-cell lymphoma. Am J Clin Pathol. 2015; 143(5): 725-7[DOI][PubMed]
  • 20. Dasa O, Ruzieh M, Oraibi O. Successful Treatment of Life-Threatening Interstitial Lung Disease Secondary to Antisynthetase Syndrome Using Rituximab: A Case Report and Review of the Literature. Am J Ther. 2015; [DOI][PubMed]
  • 21. Timlin H, Lee SM, Manno RL, Seo P, Geetha D. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Semin Arthritis Rheum. 2015; 45(1): 67-9[DOI][PubMed]
  • 22. Kashiwagi H, Tomiyama Y. [Recent advances in pathophysiology and treatment of immune thrombocytopenia]. Rinsho Ketsueki. 2015; 56(2): 177-84[DOI][PubMed]
  • 23. Alsharoqi I. Remarkable response of seropositive neuromyelitis optica to rituximab therapy – First report from kingdom of Bahrain. Mult Scler Relat Disord. 2014; 3(6): 761[DOI]
  • 24. Graves J, Vinayagasundaram U, Mowry EM, Matthews IR, Marino JA, Cheng J, et al. Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. Mult Scler Relat Disord. 2014; 3(2): 244-52[DOI][PubMed]
  • 25. Beres SJ, Graves J, Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatr Neurol. 2014; 51(1): 114-8[DOI][PubMed]
  • 26. Bonnan M, Ferrari S, Bertandeau E, Demasles S, Krim E, Miquel M, et al. Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials. Curr Drug Targets. 2014; 15(13): 1205-14[PubMed]
  • 27. He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H, et al. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2013; 12[DOI]
  • 28. Tolou-Ghamari Z. Demographic Analysis of Patients With Multiple Sclerosis; Individual Variability Related to the Time Interval. Arch Neurosci. 2015; 2(3)[DOI]
  • 29. von Budingen HC, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol. 2015; 73(3-4): 238-46[DOI][PubMed]
  • 30. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009; 66(4): 460-71[DOI]
  • 31. Derwenskus J, Lublin FD. Future treatment approaches to multiple sclerosis. Handb Clin Neurol. 2014; 122: 563-77[DOI][PubMed]
  • 32. Svenningsson A, Bergman J, Dring A, Vagberg M, Birgander R, Lindqvist T, et al. Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. Neurol Neuroimmunol Neuroinflamm. 2015; 2(2)[DOI][PubMed]
  • 33. Minagar A. Current and future therapies for multiple sclerosis. Scientifica (Cairo). 2013; 2013: 249101[DOI][PubMed]
  • 34. Gasperini C, Haggiag S, Ruggieri S. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. Expert Opin Investig Drugs. 2013; 22(10): 1243-53[DOI][PubMed]
  • 35. Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009; 9(1): 10-25[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments